Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Examining the impact of bone morphogenetic protein receptor type II (BMPR-II) loss on the expression of the splicing factor 3B complex

EF 2018-19

Résumé
Pulmonary arterial hypertension (PAH) is a fatal disease that causes blockage and tightening of arteries in the lungs. This increases blood pressure in the lungs. If individuals with PAH do not receive treatment, they will die from right heart failure in 2-3 years. Unfortunately, current treatments only treat the symptoms of PAH, and have little impact on disease progression and death. Many individuals with PAH have a mutation in the gene BMPR2, which encodes a protein receptor. This mutation is found in 70% of patients who inherit PAH and 20% of individuals who develop PAH for unknown reasons. An individual with a BMPR2 mutation has a 20,000 times greater risk of developing PAH than someone who does not; however, how BMPR2 mutations cause PAH is still not fully understood. BMPR2 mutations cause increased cell growth in pulmonary arteries, which gives PAH characteristics that are similar to cancer. In addition, these mutations may also influence the type of genes expressed by a cell, through a process known as mRNA splicing. Splicing is regulated by many proteins, including proteins of the SF3B complex. Preliminary studies have suggested a link between SF3B proteins and BMPR2, as well as to certain cancers. Our work will test if BMPR2 loss influences the expression or interactions of two specific SF3B proteins, SF3B3 and SF3B4. The goal of this project is to identify whether these two SF3B subunits are involved in PAH development when BMPR2 is mutated. This will broaden the current understanding of BMPR2 effects in PAH, and could lead to the development of improved treatments for this disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406478
Name
Whitford Mara
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Examining the impact of bone morphogenetic protein receptor type II (BMPR-II) loss on the expression of the splicing factor 3B complex
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Protein-Protein Interactions; Pulmonary Arterial Hypertension; Splicing Factors; Tgf-Beta Signalling
Abstract
Pulmonary arterial hypertension (PAH) is a fatal disease that causes blockage and tightening of arteries in the lungs. This increases blood pressure in the lungs. If individuals with PAH do not receive treatment, they will die from right heart failure in 2-3 years. Unfortunately, current treatments only treat the symptoms of PAH, and have little impact on disease progression and death. Many individuals with PAH have a mutation in the gene BMPR2, which encodes a protein receptor. This mutation is found in 70% of patients who inherit PAH and 20% of individuals who develop PAH for unknown reasons. An individual with a BMPR2 mutation has a 20,000 times greater risk of developing PAH than someone who does not; however, how BMPR2 mutations cause PAH is still not fully understood. BMPR2 mutations cause increased cell growth in pulmonary arteries, which gives PAH characteristics that are similar to cancer. In addition, these mutations may also influence the type of genes expressed by a cell, through a process known as mRNA splicing. Splicing is regulated by many proteins, including proteins of the SF3B complex. Preliminary studies have suggested a link between SF3B proteins and BMPR2, as well as to certain cancers. Our work will test if BMPR2 loss influences the expression or interactions of two specific SF3B proteins, SF3B3 and SF3B4. The goal of this project is to identify whether these two SF3B subunits are involved in PAH development when BMPR2 is mutated. This will broaden the current understanding of BMPR2 effects in PAH, and could lead to the development of improved treatments for this disease.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Whitford, Mara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~